ASRT vs LEN · rev $125.0M vs rev $34.19B
Assertio Therapeutics Inc (ASRT) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Assertio Therapeutics Inc (ASRT) is a drug manufacturers - specialty & generic company listed on US.
LEN (LEN) common stock.
Latest reported ASRT revenue for 2024-12-31 was $125.0M. Net income was -$21.6M. Revenue was down 17.8% from 2023-12-31 to 2024-12-31. ASRT currently screens at market cap $151.5M.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
ASRT currently screens at market cap $151.5M. LEN currently screens at market cap $0.
Not investment advice. Open the ASRT and LEN stock pages for the full models.
Not investment advice.